---
layout: post
title: "Processes and Practices Applicable to Bioresearch Monitoring Inspections; Guidance for Industry; Availability"
date: 2026-02-04 21:37:10 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-23404
original_published: 2025-12-19 00:00:00 +0000
significance: 8.00
---

# Processes and Practices Applicable to Bioresearch Monitoring Inspections; Guidance for Industry; Availability

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 19, 2025 00:00 UTC
**Document Number:** 2025-23404

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Processes and Practices Applicable to Bioresearch Monitoring Inspections." This final guidance is being issued to comply with the Food and Drug Omnibus Reform Act of 2022, which directs the Agency to issue guidance describing the processes and practices applicable to inspections of sites and facilities inspected under FDA's Bioresearch Monitoring inspection program, to the extent not specified in existing publicly available FDA guides and manuals. The guidance covers the following: the types of records and information required to be provided, best practices for communication between FDA and industry in advance of or during an inspection or request for records or other information, and other inspections-related conduct.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/19/2025-23404/processes-and-practices-applicable-to-bioresearch-monitoring-inspections-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2025-23404

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
